Altimmune, Inc. (ALT) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 43 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026before open 43 8-K
Q2 FY2026Wed, Aug 12, 2026before open 43 8-K
Q1 FY2026Wed, May 13, 2026before open 43 8-K
Q4 FY2025Thu, Mar 5, 2026before open 64 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Tue, Aug 12, 2025before open 43 8-K
Q1 FY2025Tue, May 13, 2025before open 43 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Enrollment is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027 ​ Scientific Data on Pemvidutide in MASH and AUD Presented at AASLD The Liver Meeting® 2026" exhibit
Q3 FY2026 "Net loss for the three months ended September 30, 2026, was $31.6 million, or $0.15 net loss per share, compared to a net loss of $19.0 million, or $0.21 net loss per share, in the same period in 2025 ​ ​ ​ ​ Conference Call Information: ​ ​ Date: November 12, 2026 Time: 8:30 a.m. Eastern Time Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at https://ir.altimmune.com/investors ." exhibit
Q2 FY2026 "In July 2026, the Company completed patient enrollment in the RESTORE Phase 2 trial of pemvidutide in ALD o The RESTORE trial is a 48-week study evaluating the safety and efficacy of pemvidutide versus placebo in approximately 120 patients with liver disease due to excessive alcohol consumption o The trial enrolled patients with ALD and a history of chronic and heavy drinking at baseline o To support future regulatory discussions, the Company has amended the trial protocol to more fully evaluate the liver benefits pemvidutide may provide after one year of treatment in the ALD population o The " exhibit
Q2 FY2026 "Net loss for the three months ended June 30, 2026, was $22.8 million, or $0.12 net loss per share, compared to a net loss of $22.1 million, or $0.27 net loss per share, in the same period in 2025 ​ Conference Call Information: ​ ​ Date: August 12, 2026 Time: 8:30 a.m. Eastern Time Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at https://ir.altimmune.com/investors ." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ALT earnings date badge

HTML

<a href="https://veritasdata.dev/company/ALT/"><img src="https://veritasdata.dev/embed/ALT.svg" alt="ALT earnings date" width="240" height="56"></a>

Markdown

[![ALT earnings date](https://veritasdata.dev/embed/ALT.svg)](https://veritasdata.dev/company/ALT/)

Script

<script async src="https://veritasdata.dev/embed/ALT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.